MedTrace Logo

At Work and Coping - Effect Study of Workcoping for Patients With Anxiety and Depression

NCT01146730 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1202

Last updated 2018-07-11

No results posted yet for this study

Summary

Mental disorders, mainly various anxiety and depressive disorders, are an increasing reason for sick leave and disability pension. Cognitive behaviour therapy (CBT) has been shown to have an effect on anxiety and depression, but the investigators know little about this in relation to employment. Close follow-up in ordinary employment increase employment participation for serious mental illness, but this is not yet investigated to the same degree for lighter mental disorders.

Center for Work-Coping (No: "Senter for Jobbmestring" - SJM) combines Cognitive behaviour therapy (CBT) and individual placement and support (IPS) and facilitation of work for people with anxiety and depression who are in danger of falling out of work.

The purpose of this project is to evaluate the effectiveness of the model in SJM. The effect will be evaluated through a randomized controlled trial (RCT) in which participants will be randomized to SJM or regular follow-up by The Norwegian Labour and Welfare Administration (NAV) or by their regular general practitioners (GP) and self-help resources. The main outcome measures are work participation with changes in mental health as a secondary outcome.

Conditions

Interventions

BEHAVIORAL

Workcoping and IPS

Maximum 15 sessions of CBT-based counseling with workcoping as primary focus in addition to work support according to the IPS-model (individual placement and support)

BEHAVIORAL

Ordinary care by GP or NAV

Ordinary care by the participants physician or the local Labour and Welfare Administration

Sponsors & Collaborators

  • Norwegian Labour and Welfare Administration

    collaborator OTHER

  • NORCE Norwegian Research Centre AS

    lead OTHER

Principal Investigators

  • Silje E Reme, PhD · NORCE Norwegian Research Centre AS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2016-03-31
Completion
2018-05-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01146730 on ClinicalTrials.gov